Perception of risk: the state of COX-2 selective inhibitors.

被引：2
作者：
Simon L.S. [1 ]
Strand V. [1 ]
机构：
[1] Harvard Medical School, Beth Israel Deaconess Medical Center, Suite 5A, 110 Francis Street, Boston, 02115, MA
来源：
Current Rheumatology Reports | 2005年 / 7卷 / 3期
关键词：
Celecoxib; Naproxen; Rofecoxib; Etoricoxib; Valdecoxib;
D O I：
10.1007/s11926-996-0032-4
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：163 / 166
页数：3
相关论文
共 50 条
[31]   Relative thromboembolic risks associated with COX-2 inhibitors [J].
Jones, SC .
ANNALS OF PHARMACOTHERAPY, 2005, 39 (7-8) :1249-1259
[32]   Safety update on COX-2 inhibitors [J].
Reactions Weekly, 2002, 910 (1) :2-2
[33]   COX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients [J].
Marc C Hochberg .
Arthritis Res Ther, 5
[34]   COX-2: where are we in 2003? Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patients [J].
Hochberg, MC .
ARTHRITIS RESEARCH & THERAPY, 2003, 5 (01) :28-31
[35]   Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland [J].
Girvin, B ;
Rafferty, T ;
Stevenson, MR ;
Johnston, GD .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2004, 13 (03) :153-157
[36]   Will the promise of the COX-2 selective NSAIDs come to fruition? [J].
不详 .
Drugs & Therapy Perspectives, 2001, 17 (11) :6-10
[37]   Efficacy of the newest COX-2 selective inhibitors in rheumatic disease [J].
Baraf, Herbert S. B. .
CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (22) :2228-2236
[38]   Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines [J].
Kardosh, A ;
Blumenthal, M ;
Wang, WJ ;
Chen, TC ;
Schönthal, AH .
CANCER BIOLOGY & THERAPY, 2004, 3 (01) :55-62
[39]   COX-2 inhibitors differ in their potential to cause ischaemic stroke [J].
Reactions Weekly, 2006, 1117 (1) :5-5
[40]   Carbonic anhydrase/COX-2 inhibitors in the treatment of various diseases [J].
不详 .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2004, 14 (12) :1803-1806
12345